Peptide COA checklists on TikTok: what they miss

What did @hannahlang49 actually say?

She made one genuinely useful point that most peptide content creators skip entirely: a certificate of analysis showing 99% purity does not confirm that a compound is sterile or free of bacterial endotoxins. She also outlined a four-point vetting framework covering batch-specific COAs, HPLC and mass spectrometry testing, physical inspection of the lyophilized powder, and independent third-party lab testing.

Her core argument is that paperwork from a supplier is not enough. "A 99% purity on a COA does not mean that it's safe," she says. "It does not test for endotoxins or sterility." She is right about that, and it is a point that gets buried in the typical biohacking content cycle where COA screenshots get passed around as proof of legitimacy. She also flags yellow or brown discoloration and clumping as signs of degradation, moisture exposure, or a compromised batch.

Does the science back this up?

On the endotoxin issue, yes, the science is squarely on her side. Lipopolysaccharide (LPS) contamination from gram-negative bacteria is a well-documented risk in injectable biologics produced outside pharmaceutical-grade conditions. A COA based on HPLC purity testing will not detect it.

Endotoxin testing typically requires a Limulus Amebocyte Lysate (LAL) assay or a recombinant Factor C assay, neither of which is standard in the COA documents circulating in the grey-market peptide space. Research from Petsch and Anspach (2000, Journal of Biotechnology) laid out the contamination pathways for recombinant proteins produced in E. coli systems, which is how many research peptides are synthesized. Bacterial endotoxins are pyrogens, and injection of contaminated material can trigger fever, systemic inflammation, or septic shock in severe cases. The FDA's guidelines for parenteral drug products set endotoxin limits for exactly this reason. Her claim is not alarmist. It reflects real pharmaceutical manufacturing science.

On HPLC plus mass spectrometry, she is also correct. HPLC alone tells you what percentage of the sample is the target compound. Mass spectrometry confirms molecular identity. Neither test alone is sufficient.

What did they get wrong (or right)?

She got the core biochemistry right. The endotoxin point is accurate, the dual-testing recommendation is sound, and the physical inspection guidance is reasonable. Lyophilized peptides should appear white to off-white and loosely powdered. Discoloration or caking can indicate oxidation, moisture intrusion during lyophilization, or storage failure, though it is worth noting that some peptides have naturally yellowish hues at certain concentrations, so color alone is not a definitive disqualifier.

What she did not address is the more uncomfortable layer: even if you get all four of her checkpoints right, you are still working with a compound that has not gone through clinical trials for human use in most of the indications people are using these peptides for. The COA vetting framework she describes is necessary but not sufficient for determining safety. It reduces contamination risk; it does not resolve questions about dosing, pharmacokinetics, or long-term effects. She frames the grey market as a gap in the system, which is fair, but the implication that thorough vetting makes injection safe sidesteps the larger regulatory and clinical evidence gap. That omission matters.

What should you actually know?

The grey-market peptide supply chain is genuinely poorly regulated, and her framework is a reasonable harm-reduction approach within that context. But a few things need to be stated plainly.

• Endotoxin testing (LAL assay) and sterility testing are separate from purity testing and are rarely included in COAs from research peptide suppliers. If a supplier does not provide these, you do not have a complete safety picture.
• Third-party testing is possible. Companies like Janoshik Analytical, Colmaric Analyticals, and others accept samples from individuals. Results take time and cost money, but the option exists.
• The lot number matching point she makes is legitimate. A generic COA covering an entire product line, rather than a specific batch, provides no meaningful quality assurance for the vial you are holding.
• Compounded peptides from licensed 503A or 503B pharmacies in the US operate under USP standards that include sterility and endotoxin testing requirements. They are not equivalent to research-grade grey-market products. The regulatory infrastructure exists; accessing it through legitimate medical channels is a different path than what most of this content addresses.
• No COA, however complete, substitutes for clinical oversight when injecting any bioactive compound.